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Abstract
Background:	 Acute	 thrombotic	 syndromes	 lead	 to	 atherosclerotic	 plaque	 rupture	
with	 subsequent	 thrombus	 formation,	myocardial	 infarction	 and	 stroke.	 Following	
rupture,	flowing	blood	is	exposed	to	plaque	components,	including	collagen,	which	
triggers	platelet	activation	and	aggregation.	However,	plaque	rupture	releases	other	
components	into	the	surrounding	vessel	which	have	the	potential	to	influence	plate-
let	function	and	thrombus	formation.
Objectives:	 Here	 we	 sought	 to	 elucidate	 whether	 matrix	 metalloproteinase-	13	
(MMP-	13),	a	collagenolytic	metalloproteinase	up-	regulated	in	atherothrombotic	and	
inflammatory	conditions,	affects	platelet	aggregation	and	thrombus	formation.
Results:	We	demonstrate	that	MMP-	13	is	able	to	bind	to	platelet	receptors	alphaIIb-
beta3 (αIIbβ3)	and	platelet	glycoprotein	(GP)VI.	The	interactions	between	MMP-	13,	
GPVI	 and	αIIbβ3	are	 sufficient	 to	 significantly	 inhibit	washed	platelet	 aggregation	
and	decrease	thrombus	formation	on	fibrillar	collagen.
Conclusions:	Our	data	demonstrate	a	role	for	MMP-	13	in	the	inhibition	of	both	plate-
let	 aggregation	and	 thrombus	 formation	 in	whole	 flowing	blood,	 and	may	provide	
new	avenues	of	research	into	the	mechanisms	underlying	the	subtle	role	of	MMP-	13	
in	atherothrombotic	pathologies.
K E Y W O R D S
GPVI	collagen	receptor,	Integrin	alphaIIbbeta3	(αIIbβ3),	matrix	metalloproteinase-13,	
platelets,	thrombosis
Essentials
•	 MMP-13	has	the	potential	to	influence	platelet	function	and	thrombus	formation	directly.
•	 We	sought	to	elucidate	whether	MMP-13	is	able	to	bind	to	specific	platelet	receptors.
•	 MMP-13	is	able	to	bind	to	platelet	alphaIIbbeta3	(αIIbβ3)	and	glycoprotein	(GP)VI.
•	 These	interactions	are	sufficient	to	inhibit	platelet	aggregation	and	thrombus	formation.
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1  | INTRODUCTION
Platelet-	extracellular	matrix	and	platelet–platelet	adhesions	are	cen-
tral	to	the	formation	of	thrombi.	MMP-	13	is	up-	regulated	in	inflam-
mation,	and	is	elevated	in	the	atherosclerotic	plaque,	contributing	to	
its vulnerability.1	It	is	also	implicated	in	the	progression	and	remod-
elling	of	cerebral	tissue	in	stroke.2	Plaque	rupture	releases	MMP-	13	
into	the	local	environment	where	it	has	direct	access	to	plasma	pro-
teins,	blood	cells,	and	platelets.	Following	injury	to	the	blood	vessel	
wall,	specific	platelet	receptors	mediate	platelet–collagen	and	plate-
let–platelet	interactions.	GPIbα	binds	to	immobilized	von	Willebrand	
factor	(VWF)	in	the	vessel	wall,	initiating	platelet	capture,3	and	gly-
coprotein	 (GP)VI	binds	directly	 to	collagen	and	activates	platelets.	
Integrin	α2β1	stabilises	the	early	stages	of	the	platelet-	collagen	in-
teraction,	and	integrin	αIIbβ3	supports	platelet–platelet	interactions	
mediated	by	fibrinogen	and	VWF.4–7
MMP-	2	and	-	9	have	previously	been	shown	to	bind	to	platelet	
receptors	 and/or	 to	 modulate	 platelet	 function.8–13	 Here,	 we	 hy-
pothesized	that	MMP-	13	may	also	interact	directly	with	platelet	re-
ceptors	GPVI,	integrin	α2β1,	or	the	platelet	adhesive	integrin	αIIbβ3 
to	modulate	platelet	adhesion,	aggregation	and	thrombus	formation.	
Our	work	 identifies	potential	 roles	 for	MMP-	13	 in	modulating	 the	
recruitment	or	activation	of	platelets	in	thrombotic	pathologies.
2  | METHODS
2.1 | MMP- 13 expression, purification and activation
ProMMP-	13	 and	 its	 MMP-	13	 catalytic	 (CAT,	 249-	451)	 domain	
were	 expressed,	 purified,	 activated,	 and	 dialysed	 as	 previously	 de-
scribed.14–16	 The	 structurally	 homologous	 but	 catalytically	 inactive	
proMMP-	13(E204A)	was	a	kind	gift	from	Dr.	R.	Visse	(Kennedy	Institute	
of	 Rheumatology	 Division,	 Imperial	 College	 London,	 London,	
UK).	 GST-	Hemopexin	 (HPX)	 domain	 (264-	471)	 was	 expressed	 in	
E. coli	 using	 the	 pGEX-	2T	 expression	 vector,	 the	 forward	 primer	
TCCGCGTGGATCCCTCTATGGTCCAGGAGATGAA	 and	 the	 reverse	
primer	GCAA-	ATTCCATTTTGTGGTGTTGAAGAATTCAT,	which	contain	
BamHI	and	EcoRI	restriction	sites	respectively,	as	previously	described.16
2.2 | Washed platelet preparation and platelet 
adhesion assays
Plates	were	 coated	with	 10	μg/ml	MMP-	13	 variants	 in	 Tris	 buff-
ered	 saline	 (TBS)	 for	1	h	at	24°C.	Plates	were	 then	blocked	with	
5%	 BSA	 in	 TBS	 for	 20	minutes	 at	 24°C	 and	 washed	 with	 TBS	 
prior	 to	 the	 addition	 of	 washed	 platelets.	 Platelets	 were	 puri-
fied	 and	 adhesion	 assays	 conducted	 as	 previously	 described.17,18 
Glanzmann	 thrombasthenic	 blood	 was	 kindly	 provided	 by	
Prof	 M.	 Makris,	 Royal	 Hallamshire	 Hospital,	 Sheffield,	 UK.	
GR144053	 (4-	[4-	[4-	(aminoiminomethyl)phenyl]-	1-	piperazinyl]-	1-	
piperidineacetic	acid	hydrochloride	trihydrate)	was	purchased	from	
Calbiochem,	Nottingham,	UK.	The	α2β1	 integrin-	binding	peptide	
GFOGER	 (GPC[GPP]5-	GFOGER-	[GPP]5-	GPC)	 and	 GPVI-	binding	
peptide	 CRP-XL	 (GCO-[GPO]10-GCOG);	 cross-	linked	 where	 ap-
propriate	 and	 the	 inert	 GPP10	 (GPC-	[GPP]10-	GPC)	 were	 gener-
ated	 as	 previously	 described7	 along	 with	 the	 anti–GPVI	 scFvs	
10B12	 and	 1C3	 and	 the	 non-	GPVI-	binding	 scFv	 2D419–23 which 
were	a	kind	gift	 from	Dr.	P.	 Smethurst.	Human	 fibrinogen	 type	 I	
was	purchased	from	Sigma,	UK.	Anti–α2β1	antibody	6F1	was	a	kind	
gift	from	Prof.	B.	Coller	(Mount	Sinai	Hospital,	New	York,	NY,	USA).	
RGDS	(Arg-	Gly-	Asp-	Ser)	and	cyclic	RGD	(H-	Cys-	Arg-	Gly-	Asp-	Phe-	
Pro-	Ala-	Ser-	Ser-	Cys-	OH)	were	purchased	 from	Bachem,	Weil	 am	
Rhein,	 Germany.	 The	 fibrinogen-	derived	 peptide,	 Lys-	Gln-	Ala-	
Gly-	Asp-	Val	(KQAGDV),	was	purchased	from	Innovagen,	Sweden.	
Inhibitory	antibodies/compounds	were	used	at	10	μM	(6F1,	10B12,	
1C3,	2D4,	 cRGD,	GR144053,	KQAGDV)	or	100	μmol	L−1	 (fibrino-
gen	and	RGDS).
2.3 | Flow cytometry
In	activation	experiments,	whole	blood	diluted	1:4	with	Hepes	buffered	
saline	(HBS)	was	mixed	for	10	minutes	at	24°C	with	an	equal	volume	
of	10	μg/ml	mouse	anti	P-	Selectin	 (Abcam,	Cambs,	UK)	and	the	fol-
lowing	agonists	2	mmol	L−1	proMMP-	13(E204A)	or	MMP-	13,	100	μg/
ml	CRP-	XL,	100	μg/ml	HORM®	equine	collagen	I	fibers	(Takeda,	Linz,	
Austria),	 thrombin	 activating	 peptide	 (TRAP;	 500	μmol	L−1;	 Sigma,	
UK)	 calcium	 ionophore	 A23187	 (100	μmol	L−1;	 Sigma	 UK)	 or	 HBS	
(negative	 control)	 added.	Alexa	 488	 conjugated	 anti-	mouse	 (30	μg/
ml	 final	 concentration;	 Jackson	 Immuno	 Research,	 Ely,	 UK)	 was	
then	added	and	after	10	minutes	at	24°C	 the	volume	was	made	up	
to 500 μl	with	 isotonic	 solution.	After	 30	minutes	 fluorescence	was	
measured	using	an	Accuri	C6	flow	cytometer	(BD	Biosciences,	Oxford,	
UK).	 In	 inhibition	experiments,	whole	blood	was	pre-	incubated	with	
proMMP-	13(E204A),	 GR144053	 (20	μmol	L−1)	 or	 10B12	 (10	μg/ml)	
for	20	minutes	prior	to	the	addition	of	CRP-	XL.
2.4 | Solid phase adhesion assays
Recombinant human αIIbβ3	and	GPVI	monomer	were	obtained	from	
R&D	 Systems	 (Abingdon,	 Oxford,	 UK).	 Recombinant	 extracellular	
domain	 of	 GPVI	 (GPVIex,	 comprising	 D1D2	 (amino	 acids	 1–214;	
42	kDa)	fused	with	the	Fc	domain	of	human	IgG	(GPVI-	Fc2,	150	kDa)	
was	prepared	as	previously	described.24
HB	96-	well	plates	(Nunc,	Langenselbold,	Germany)	were	coated	
with	recombinant	GPVI	monomer	or	dimer	(10	μg/ml	in	Phosphate-	
Buffered	Saline	[PBS])	for	1	h	at	24°C.	All	further	incubations	were	
performed	at	room	temperature	for	1	h	unless	otherwise	stated.	The	
wells	were	washed	three	times	with	adhesion	buffer	(1	mg/ml	BSA	in	
PBS	containing	0.1%	[v/v]	Tween-	20)	between	each	incubation	step.	
The	wells	were	then	blocked	with	50	mg/ml	BSA	in	TBS	prior	to	the	
addition	of	MMP-	13	at	a	concentration	of	83	nmol	L−1 (unless other-
wise	stated)	for	1	h	at	24°C	in	adhesion	buffer.	Rabbit	anti-	MMP-	13,	
raised	against	MMP-	13	hinge	region	 (Abcam,	Cambridge,	UK),	and	
goat	anti-	rabbit	HRP	(Dako,	Stockport,	UK)	were	added	at	a	dilution	
of	1:2000	in	adhesion	buffer	prior	to	the	addition	of	a	TMB	substrate	
system	(Sigma,	UK)	and	the	plates	read	at	450	nm.
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2.5 | Aggregometry
Washed	platelet	aggregation	was	performed	using	a	Chrono-	Log	turbi-
dimetric	aggregometer	(Labmedics,	Abingdon	on	Thames,	UK).	250	μL	
aliquots	of	platelets,	2	×	108/mL	in	calcium-	free	Tyrodes	buffer	 (CFT),	
were	pre-	incubated	for	1	h	with	80	nmol	L−1	MMP-	13	or	vehicle	con-
trol	prior	to	the	addition	of	receptor	agonists	in	a	maximum	volume	of	
5 μL.	Thrombin,	calcium	ionophore	A23187	(San	Diego,	CA,	USA),	bo-
vine	collagen	I	fibers	(Ethicon	Corp,	Somerville,	NJ,	USA),	HORM® and 
CRP–XL	were	prepared	and	employed	to	activate	platelets	as	previously	
described.25,26	Aggregations	were	allowed	to	proceed	for	5	minutes.
2.6 | Cleavage of platelet receptors and their 
substrates by MMP- 13
Recombinant	 human	 (rh)GPVI,	 purified	 αIIbβ3 (100 μg/mL,	 R&D	
Systems)	 and	 human	 fibrinogen	 type	 I	 (1	mg/mL)	 were	 incubated	
with	 MMP-	13	 or	 MMP-	13(E204A)	 (8	μmol	L−1	 final	 concentration)	
for	2	h	at	37°C.	An	equal	volume	of	Tris	buffer	was	used	as	a	nega-
tive	control.	Reducing	sample	buffer	was	then	added	to	the	mixture	
in	preparation	for	electrophoresis	and	Western	blotting.
2.7 | In vitro sheddase activity assays
Dialysed	MMP-	13	at	a	 final	 concentration	of	130	nmol	L–1 was in-
cubated	 with	 washed	 platelets	 for	 60	minutes	 at	 37°C.	 Positive	
controls	for	shedding	included	thrombin	(1	U/mL,	Sigma,	UK)	com-
bined	with	fibrous	type	I	collagen	(1	mg/mL),	the	calcium	ionophore	
A23187	 (1	μg/mL).	 The	platelets	were	 then	pelleted	 at	1500	g	 for	
1	minute.	 The	 supernatants	 were	 aspirated	 and	 centrifuged	 again	
to	ensure	platelet	depletion.	This	new	supernatant	was	retained	for	
analysis.	Where	indicated,	platelet	lysate	was	resuspended	in	reduc-
ing	sample	buffer.
2.8 | Electrophoresis and Western blotting
Protein	samples	in	reducing	sample	buffer	were	boiled	for	5	minutes	
and	applied	to	4-	12%	NuPage	Gels	and	separated	by	electrophore-
sis	 using	 the	Xcell	 SureLock	 system	 (Invitrogen,	Paisley,	UK)	 under	
reducing	conditions.	Proteins	were	 then	 transferred	on	 to	nitrocel-
lulose	membrane	 (Millipore,	Bedford,	UK)	at	40	V	overnight	at	4°C	
using	 a	 Mini	 Protean	 II	 system	 (Bio-	Rad,	 Hemel	 Hempstead,	 UK).	
Following	transfer,	the	PVDF	was	blocked	(5%	nonfat	dry	powdered	
F IGURE  1 Washed	platelet	adhesion	
assays.	(A)	Platelets	adherent	to	10	μg/ml	
coated	MMP-	13	variants	in	the	presence	
of	2	mmol	L−1	Mg2+	(red	bars)	or	2	mmol	L−1 
EDTA	(orange	bars)	where	stated.	
Where	appropriate,	platelets	were	pre-	
incubated	with	anti-	GPVI,	αIIbβ3 or α2β1 
antagonists.	BSA	and	GPP10 were used as 
Mg2+-	independent	negative	controls.	The	
platelet	α2β1	binding-	peptide	GFOGER	
was	included	as	an	Mg2+	dependent	
positive	control.	*P <	.05;	**P < .01; †(one- 
way anova	and	Holm	multiple	comparison	
test)	relative	to	untreated	platelets	in	
either	the	presence	of	Mg2+	or	EDTA,	
as	appropriate.	(B)	Inhibition	of	platelet	
adhesion	to	CRP	by	anti-	GPVI	scFvs	as	
described	above	(C)	Platelets	adherent	
to	MMP-	13(E204A)	and	MMP-	13	CAT	
and	HPX	domains.	CRP-	XL	was	used	as	
a	positive	control.	**P < .01 (one- way 
anova	and	Holm	multiple	comparison	test)	
relative	to	adhesion	to	MMP-	13(E204A).	
Data	represent	mean	A405	±	SE	of	three	
experiments
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milk,	0.1%	Tween	20	in	TBS)	for	1	h	and	primary	antibody	was	then	
added	(1:1000	dilution)	and	incubated	for	2	h	at	room	temperature.	
Anti-	human	GPVI	was	a	kind	gift	from	Dr.	P.	Smethurst,	and	anti-	β3 
was	obtained	 from	Abcam,	Cambridge,	UK.	Following	washes	with	
TBST,	 the	membrane	was	 incubated	with	HRP	conjugated	 second-
ary	 antibody	 (1:10000	 dilution/TBST)	 for	 1	h	 at	 24°C.	 The	 PVDF	
was	developed	using	a	chemiluminescent	substrate	(GE	Healthcare,	
Amersham,	Bucks,	UK).
2.9 | Whole blood perfusion experiments
Whole	 blood	 was	 pre-	incubated	 with	 either	 carrier	 (TBS)	 or	
80	nmol	L−1	MMP-	13	for	1	h	prior	to	perfusion	over	10	μg/mL	type	I	
fibrous	collagen	as	previously	described.17,25	Where	indicated,	slides	
were	coated	with	MMP-	13(E204A)	alone	as	a	(negative)	control.
3  | RESULTS
Adhesion	 assays	 were	 performed	 in	 the	 presence	 of	 2	mmol	L−1 
EDTA	 or	 Mg2+	 to	 ablate	 or	 support	 integrin-	mediated	 adhesion.	
Platelet	 adhesion	 to	 MMP-	13	 preparations	 was	 significantly	 re-
duced,	 but	 not	 abolished,	 by	 EDTA,	 suggesting	 both	 integrin-	
dependent	 and	 -	independent	 contributions,	 whereas	 EDTA	 fully	
abolished	binding	to	the	collagen-	binding	integrin-	specific	peptide	
GFOGER	(Figure	1A).
Platelet	pre-	incubation	with	the	αIIbβ3	antagonists,	GR144053,	
cRGD,	and	RGDS,	and	with	anti-	GPVI	scFv	10B12	and	1C3,	all	caused	
a	substantial	and	significant	reduction	(P < .01)	in	platelet	adhesion	
to	proMMP-	13	(Figure	1A),	with	residual	adhesion	being	observed	in	
the	presence	of	EDTA	remaining	above	negative	control	levels	(non-
specific	substrates).	This	may	indicate	cooperative	binding	to	αIIbβ3 
F IGURE  2 Competition,	GPVI	and	Glanzmann	platelet	binding	assays.	(A)	MMP-	13(E204A)	and	either	10B12	or	GR144053	were	used	to	
obtain	IC50	values	for	the	inhibition	of	washed	platelet	adhesion	to	10	μg/ml	coated	fibrinogen	(i,	iii)	or	CRP	(ii,	iv),	respectively.	(v)	Adhesion	
of	MMP-	13(E204A)	to	recombinant	human	GPVI	monomer	and	dimer.	Plates	were	coated	with	10	μg/ml	GPVI	or	BSA	as	a	negative	control.	
MMP-	13(E204A)	at	a	concentration	of	83	nM	was	allowed	to	adhere	for	1	h	at	room	temperature,	then	detected	using	an	antibody	directed	
at	the	MMP-	13	linker	region,	as	described	in	Methods.	Data	represent	mean	A450	±	SE	of	three	experiments.	(B)	Platelets	from	a	healthy	
donor	(red	bars)	and	from	a	Glanzmann	thombasthenic	individual	(orange	bars)	were	allowed	to	adhere	to	MMP-	13,	fibrinogen	and	CRP-	XL	
coated	plates.	Where	appropriate,	platelets	were	pre-	incubated	with	anti-	GPVI	(1C3),	or	αIIbβ3	antagonists	as	described	for	Figure	1.	Data	
represent	mean	A405	±	SE	of	duplicate	readings	for	one	experiment	due	to	the	rarity	of	the	Glanzmann	donor
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and	GPVI.	Interaction	between	MMP-	13	and	integrin	α2β1 was less 
prominent,	since	blocking	antibody	6F1	had	just	a	small	effect,	and	
was	not	studied	further.	Platelet	pre-	incubation	with	the	fibrinogen-	
derived	peptide,	KQAGDV,	had	no	effect	on	platelet	adhesion,	indi-
cating	that	MMP-	13	binds	αIIbβ3	closer	to	the	primary	RGD-	binding	
site.	Soluble	fibrinogen	also	did	not	block	platelet	adhesion	to	MMP-	
13,	in	line	with	the	need	for	platelet	activation	for	soluble	fibrinogen	
binding	to	αIIbβ3	to	occur,	whereas	immobilized	fibrinogen	is	already	
competent	to	bind.	The	GPVI-	specific	scFv,	1C3,	does	not	target	the	
collagen-	binding	site	at	the	apex	of	GPVI,	unlike	10B12,	and	was	un-
able	to	inhibit	the	adhesion	of	washed	platelets	to	CRP	(Figure	1B).	
1C3	 binding	 requires	 both	GPVI	 Ig	 domains	 and	 is	 thought	 to	 re-
duce	platelet	activation	by	inhibiting	receptor	clustering;	its	epitope	
includes	 isoleucine	 148,21,23	 located	 in	 strand	 E	 on	 the	 opposite	
face	of	D2	to	the	crystal	structure	dimerization	interface	located	in	
strand G.24	An	indifferent	control,	the	anti-	HLA-	A2	scFv,	2D4,	was	
inactive	in	these	experiments.	In	subsequent	experiments,	only	low	
platelet	binding	was	observed	to	isolated	CAT	and	HPX	domains	of	
MMP-	13	in	comparison	with	the	intact	protein	(Figure	1C),	 indicat-
ing	that	neither	domain	alone	governs	the	interaction	between	the	
MMP	and	platelets,	and	supporting	the	possibility	that	two	sites	on	
MMP-	13	cooperate	to	bind	αIIbβ3	and	GPVI.
Competition	assays	in	which	washed	platelets	were	pre-	incubated	
with	increasing	amounts	of	the	catalytically-	dead	MMP-	13(E204A)	
provided	 further	evidence	 that	MMP-	13	 interacts	with	both	GPVI	
and αIIbβ3;	like	GR144053	and	10B12,	MMP-	13	can	compete	αIIbβ3 
off	immobilized	fibrinogen	and	GPVI	off	CRP	(IC50	150	ng/mL	and	
~10	ng/mL	 respectively;	 Figures	2A[i-	iv]).	 Solid	 phase	 binding	 as-
says	 to	 coated	 isolated	 receptors	 revealed	 that	MMP-	13	was	 able	
to	bind	weakly	 to	GPVI	monomer,	but	strongly	 to	 the	GPVI	dimer	
(Figure	2A[v]).	Similar	assays	of	adhesion	to	recombinant	αIIbβ3 re-
vealed	some	binding	of	its	native	ligand,	fibrinogen,	but	little	or	no	
binding	of	MMP-	13,	regardless	of	whether	Mg2+,	Mn2+,	or	Ca2+ was 
present,	nor	could	we	detect	binding	of	MMP-	13	to	purified	αIIbβ3 
(results	not	shown).	Adhesion	of	αIIbβ3-	null	Glanzmann	platelets	to	
MMP-	13,	however,	was	markedly	reduced	(Figure	2B[i]).	Blockade	of	
αIIbβ3	on	healthy	platelets	 resulted	 in	 the	 same	adhesion	 level	 as	
seen	 for	αIIbβ3-	null	 platelets.	As	 expected,	 binding	 of	Glanzmann	
platelets	to	fibrinogen	was	abolished	(Figure	2B[ii])	and	to	CRP	was	
unaffected	(Figure	2B[iii]).	Our	results	indicate	that,	whilst	MMP-	13	
appears	able	to	bind	to	αIIbβ3	on	the	platelet	surface,	recombinant	
αIIbβ3	used	here	cannot	reproduce	this	effect.
Whilst	it	was	able	to	cleave	the	recombinant	αIIbβ3 β- chain and 
GPVI	 in	 solution,	 as	well	 as	 fibrinogen	α and β	 chains	 (Figure	3A),	
F IGURE  3 Platelet	receptor	cleavage	
and	shedding	assays.	(A)	Degradation	
analysis	of	recombinant	platelet	
receptors	by	active	and	MMP-	13(E204A).	
Recombinant	human	(rh)GPVI	and	
purified	αIIbβ3	and	fibrinogen	type	I	
were	incubated	with	MMP-	13	or	MMP-	
13(E204A)	for	2	h	at	37°C.	An	equal	
volume	of	Tris	buffer	was	used	as	a	
negative	control.	Samples	were	subjected	
to	electrophoresis	under	reducing	
conditions	and	Coomassie	stained.	Images	
are	representative	of	three	experiments.	
(B)	Shedding	analysis	of	platelet	receptors.	
Washed	platelets	were	incubated	with	the	
calcium	ionophore	A23187,	a	thrombin	
and	collagen	type	I	mixture	or	MMP-	
13	for	1	h	at	37°C.	The	platelets	were	
then	pelleted,	the	supernatant	isolated	
and	subjected	to	SDS-	PAGE	under	
reducing	conditions	and	Western	blotted.	
Platelet	GPVI	and	the	integrin	β3 chain 
were	detected	using	the	appropriate	
antibodies as described in materials and 
methods.	Recombinant	human	GPVI	or	
αIIbβ3	were	loaded	onto	the	gels	where	
appropriate	as	positive	controls.	Images	
are	representative	of	three	experiments
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MMP-	13	was	unable	to	either	cause	or	mediate	shedding	of	either	
receptor	in	situ	(Figure	3B).
Pre-	incubation	 of	 washed	 platelets	 for	 1	h	 with	 80	nmol	L−1 
MMP-	13(E204A)	significantly	reduced	platelet	aggregation	to	a	se-
ries	of	agonists,	and	for	the	mid-	range	dose	of	each,	analyzed	using	
two- way anova,	 the	 inhibitory	 effect	 of	 MMP-	13	 was	 significant	
(P < .01).	Prominent	amongst	these	stimuli	were:	CRP-	XL,	ionophore	
A23187,	and	bovine	fibrillar	collagen	I,	for	which	it	was	easier	to	es-
tablish	mid-	range	doses	than	for	thrombin	and	equine	fibrillar	colla-
gen.	A	summary	of	results	is	shown	in	Figure	4A	and	representative	
traces	in	Figure	4B.	MMP-	13	does	not	activate	platelets	measured	by	
flow	cytometry:	no	change	in	fluorescence	using	the	anti-	P-	Selectin	
antibody	 was	 observed	 following	 the	 incubation	 of	 whole	 blood	
with	 pro-	MMP-	13(E204A)	 or	 MMP-	13,	 whereas	 clear	 expression	
was	 seen	 following	 treatment	 with	 CRP-	XL,	 TRAP,	 HORM®,	 and	
ionophore	A23187	(Figure	5A).	 In	addition,	MMP-	13	does	not	pro-
mote	the	aggregation	of	washed	platelets	(Figure	4B[i]).	Subsequent	
flow	cytometry	experiments	revealed	that	unlike	the	anti-	GVI	scFv	
10B12,	neither	proMMP-	13(E204A)	nor	GR144053	(a	potent	αIIbβ3 
antagonist)	are	able	 to	alter	 secretion	 following	platelet	activation	
via	CRP-	XL	(Figure	5B).	This	would	suggest	that	in	solution,	the	poly-
meric	CRP-	XL	is	a	more	potent	ligand	than	MMP-	13,	and	that	the	in-
teraction	of	MMP-	13	with	αIIbβ3	predominates	over	that	with	GPVI.
We	 investigated	 the	 influence	of	MMP-	13	or	MMP-	13(E204A)	
on	platelet	adhesion	and	activation	 in	flowing	blood	in	vitro,	using	
fibrillar	collagen	I	coatings	and	a	shear	rate	of	1000	s−1.	Pre–incuba-
tion	of	whole	blood	with	MMP-	13	resulted	in	significantly	reduced	
platelet	surface	coverage	(P < .05),	mean	thrombus	height	(P < .01),	
F IGURE  4  Inhibition	of	platelet	
aggregation	by	MMP-	13(E204A).	
Different	agonists	were	added	to	washed	
platelets	following	pre-	incubation	with	
80	nmol	L−1	MMP-	13(E204A).	The	
equivalent	volume	of	0.01	mol	L−1 acetic 
acid	was	used	as	a	negative	control.	
Mean	donor	responses	performed	in	
duplicate	and	repeated	three	times	
with	different	donors	are	shown	in	(A),	
and	representative	individual	traces	
in	response	to	MMP-	13	only,	A23187,	
thrombin,	cross-	linked	collagen	related	
peptide	(CRP-	XL),	HORM®	and	type	I	
collagen	shown	in	(B)
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and	 ZV50 (P < .05),	 using	 one-	way	 anova	 and	 Holm	 multiple	 com-
parison	 test;	 Figure	6A(i-	iii).	 ZV50	 is	 the	 height	within	 a	 Z-	stack	 at	
which thrombus volume = 50% and describes the activation state 
of	adhered	platelets	in	flowing	human	blood.25	Data	obtained	using	
pre-	incubations	 with	 MMP-	13(E204A)	 reached	 significance	 only	
for	mean	thrombus	height	(P < .05,	Figure	6A[ii]).	MMP-	13(E204A)-	
coated	slides	were	not	able	to	support	platelet	adhesion	under	flow	
(Figure	6A[i-	iii]).	These	results	indicate	that	the	interaction	of	MMP-	
13(E204A)	 with	 platelet	 GPVI	 and	 αIIbβ3	 is	 sufficient	 to	 reduce	
platelet	thrombus	height.	Catalytically	active	MMP-	13,	whilst	unable	
to	cleave	these	receptors	off	the	platelet	surface,	appears	more	able	
to	inhibit	platelet	deposition.	MMP-	13	co-	coated	with	collagen	type	
I	did	not	significantly	alter	platelet	aggregate	formation	under	flow	
conditions	(Figure	6B[i-	iii]).	Interaction	of	active	MMP-	13	with	other	
blood	components	is	not	excluded	by	the	present	work,	and	further	
study is indicated.
4  | DISCUSSION
We	have	previously	 shown	 that	degradation	by	MMP-	13	has	 the	
potential	 to	modulate	 platelet	 adhesion	 to	 collagen.17	MMPs	 are	
zymogens;	 proteolysis	 is	 required	 to	 expose	 their	 catalytic	 site.	
Here	we	show	that	surprisingly,	all	forms	of	MMP-	13,	pro-	and	ac-
tive	wild	type	enzyme	as	well	as	their	catalytically	inactive	mutant	
counterparts,	were	 able	 to	 support	 a	 high	 level	 of	 platelet	 adhe-
sion under static conditions. This adhesion was inhibited by the 
anti-	GPVI	scFvs	10B12	and	1C3	suggesting	that	the	relatively	large	
MMP-	13	occludes	the	sites	of	both	10B12	and	1C3	binding	on	the	
receptor.	MMP-	13	was	also	able	to	bind	strongly	to	the	GPVI	dimer.	
Although	GPVI	dimerization	increases	upon	platelet	activation,	di-
meric	GPVI	is	also	present	on	resting	platelets	and	is	required	for	
their	 initial	 interaction	 with	 exposed	 collagen.26	 Crystallography	
of	the	proMMP-	13	structure	in	complex	with	pro-	domain	peptides	
revealed	a	dimeric	form	as	an	HPX-	mediated	dimer	like	some	other	
metalloproteinases,	although	 in	this	study,27	MMP-	13	was	not	di-
meric	in	solution.	Conceivably,	interaction	of	MMP-	13	with	platelet	
surface	GPVI	dimer	may	provide	a	template	for	dimerization	of	the	
MMP.	Platelet	adhesion	to	MMP-	13	was	also	inhibited	by	the	anti-	
αIIbβ3	compound	GR144053,	and	binding	of	Glanzmanns	αIIbβ3- 
null	 platelets	 to	 MMP-	13	 was	 significantly	 reduced.	 Following	
pre-	incubation	 of	 washed	 platelets	 with	 MMP-	13,	 neither	 GPVI	
nor αIIbβ3	 was	 shed	 from	 the	 platelet	 surface.	 It	 would	 appear,	
therefore,	that	whilst	able	to	bind	to	platelet	αIIbβ3	and	GPVI,	the	
orientation	of	MMP-	13	on	the	platelet	surface	does	not	allow	ac-
cess	of	its	CAT	domain	to	the	cleavage	site,	which,	for	other	shed-
dases,	resides	close	to	the	transmembrane	region	and	is	regulated	
by membrane structure28	 or	 substrate	 phosphorylation.29	 Pre-	
incubation	with	MMP-	13	did	not	result	in	platelet	activation	or	ag-
gregation.	Here	it	is	worth	noting	that	MMP-	13	has	been	reported	
F IGURE  5 Activation	of	platelets	in	whole	blood.	Whole	blood	was	mixed	with	anti	P-	Selectin	and	the	agonists	2	mmol	L−1	proMMP-	
13(E204A)/MMP-	13,	100	μg/ml	CRP-	XL,	100	μg/ml	HORM®	equine	collagen	I	fibers,	thrombin	activating	peptide	(TRAP;	500	μmol	L−1)	
calcium	ionophore	A23187	(100	μmol	L−1)	or	HBS	(negative	control)	added.	Alexa	488	conjugated	anti-	mouse	was	then	added	and	after	
10	minutes	at	24°C	the	volume	was	made	up	to	500	μl	with	isotonic	solution.	After	30	minutes	fluorescence	was	measured	using	an	Accuri	
C6	flow	cytometer	(BD	Biosciences,	Oxford,	UK).	Data	represent	mean	A450	±	SE	of	three	separate	donors.	**P < .005; (one- way anova and 
Holm	multiple	comparison	test)
P- selectin expression following agonist addition(A) (B) P- selectin expression following inhibitor
                         addition
**
**
**
**
4000
3500
3000
2500
2000
M
ea
n 
Fl
uo
re
sc
en
ce
 (F
L1
-A
)
M
ea
n 
Fl
uo
re
sc
en
ce
 (F
L1
-A
)
H
BS
HBS
Pr
oM
M
P-
13
(E
20
4A
)
13
(E
20
4A
)
G
R1
44
05
3
10
B1
2
M
M
P-
13
H
O
RM
CR
P-
XL
CRP-XL
TR
AP
A2
31
87
pr
oM
M
P-
1500
1000
500
4000
4500
5000
3500
3000
2500
2000
1500
1000
500
ns
ns
**
**
8  |     HOWES Et al.
to	cleave	and	thus	activate	PAR-	1	on	cardiac	cells.30 This has not 
been	demonstrated	on	platelets,	and	may	result	in	platelet	activa-
tion concomitant with αIIbβ3	 inhibition,	however	 in	 this	case	 the	
catalytically	 inactive	 proMMP-	13(E204A)	 is	 rendered	 unable	 to	
cleave	the	PAR-	1	receptor.
Coated	as	a	substrate,	MMP-	13	is	independently	unable	to	sup-
port	platelet	adhesion	in	whole	flowing	blood,	and	its	colocalization	
with	collagen	does	not	result	 in	an	 increase	 in	platelet	binding.	 In	
solution	however,	MMP-	13	 is	able	to	 interact	with	platelet	recep-
tors	GPVI	and	αIIbβ3	thereby	modulating	both	platelet	aggregation	
and	thrombus	formation	under	flow.	Whilst	MMP-	13	is	able	to	com-
pete	with	immobilized	CRP-	XL	for	occupation	of	the	GPVI	receptor,	
our	flow	cytometry	experiments	reveal	that	the	interaction	of	the	
MMP	with	platelets	 is	 insufficient	to	compete	with	the	polymeric	
solution-	phase	CRP-	XL	 and	 so	 alter	 platelet	 secretion.	 In	 this	 re-
spect,	it	behaves	much	like	the	αIIbβ3	antagonist,	GR144053,	and	
it	would	 appear	 therefore	 that	 the	 inhibitory	 effects	 of	MMP-	13	
in	 solution	 are	 mediated	 predominantly	 through	 αIIbβ3.	 At	 con-
centrations	comparable	to	those	reached	in	stroke	patient	plasma	
and	 found	 to	correlate	with	severity	of	 infarction,31	MMP-	13	can	
interact	with	both	GPVI	and	αIIbβ3,	and	can	compete	with	CRP	and	
fibrinogen	for	occupation	of	these	receptors.	MMP-	13	is	unable	to	
cleave	GPVI	and	αIIbβ3	from	the	platelet	surface	however,	and	ap-
pears	 to	 exert	 its	 effects	 by	 direct	 physical	 blockade	of	 receptor	
engagement.
Until	now,	the	role	of	MMP-	13	in	atherothrombosis	has	been	con-
sidered	to	be	restricted	to	collagen	proteolysis	and	remodelling,	ren-
dering	plaque	more	friable	and	prone	to	rupture.1	However,	MMPs	
are	now	emerging	as	important	mediators	of	platelet	function.32,33 
MMPs	-	1	and	-	2	are	released	from	activated	platelets	where	they	co-
localize	with	integrins	at	the	sites	of	platelet–platelet	interaction.10,34 
Active	 MMP-	1	 and	 -	2	 can	 stimulate	 platelet	 function,	 suggesting	
F IGURE  6 Platelet	adhesion	and	
thrombus	deposition	on	fibrillar	type	I	
collagen.	Untreated	whole	blood	and	
blood	pre-	incubated	with	80	nmol	L−1 
MMP-	13	or	negative	control	where	stated	
was	drawn	through	a	flow	chamber	for	
5	minutes	over	(A)	collagen	type	I	fibers	
or	(B)	collagen	type	I	fibers	co-	coated	
with	MMP-	13	using	a	syringe	pump	to	
generate	a	wall	shear	rate	of	1000	s−1,	
corresponding	to	arteriolar	conditions.	
Surface	coverage	(i)	mean	height	(ii)	
and	(iii)	ZV50	are	the	mean	taken	from	
a	minimum	of	three	different	donors	as	
measured	using	confocal	microscopy.	
*P <	.05;	**P < .01; (one- way anova and 
Holm	multiple	comparison	test)	relative	to	
MMP-	untreated	platelets
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receptor	engagement	and	proteolysis.34,35	MMPs	in	atherosclerotic	
lesions,	released	from	the	injured	vessel	wall	itself	or	from	platelets	
and	monocytes,	and	that	can	also	interact	with	platelets,	are	likely	
to	 interfere	 with	 the	 progression	 of	 plaque	 rupture,	 subsequent	
thrombosis	 and	 its	 associated	 pathologies	 including	 stroke,	 reper-
fusion	 injury,	 and	 hemorrhagic	 transformation.	 Indeed,	 these	 pro-
cesses	are	associated	with	an	upregulation	of	MMP	activity.2,31,36 In 
mice,	MMP-	13	is	the	key	mediator	of	collagen	degradation	in	ather-
oma	and	confers	 instability	onto	 the	vulnerability	plaque	cap.37–39 
Disruption	of	the	blood	brain	barrier	 (BBB)	by	MMPs	is	associated	
with	 hemorrhagic	 transformation	 following	 ischemic	 stroke,36,40,41 
whilst	MMPs	 -	9	 and	 -	13	 are	 implicated	 in	 the	 early	 pathology	 of	
stroke	progression,	and	plasma	MMP-	13	levels	correlate	with	lesion	
volume.2,31	In	addition,	the	platelet	collagen	receptor	GPVI	has	been	
identified	in	models	of	models	of	reperfusion	injury,42 is associated 
with	 increased	 risk	 of	 stroke	 development,	 and	 is	 also	 seen	 after	
ischemic	stroke.43
Here	we	demonstrate	that	MMP-	13	can	exert	an	antithrombotic	
effect;	 inhibiting	 platelet	 aggregation	 and	 thrombus	 formation	 in	
flowing	whole	blood.	It	may	be	that	this	metalloproteinase	has	mul-
tiple	roles	in	the	pathology	of	ischemic	stroke;	firstly	by	undermin-
ing	 the	 stability	of	 the	 fibrous	 cap	of	 atheroma	and	 so	promoting	
its	rupture,	then	modulating	the	BBB	to	increase	bleeding	risk,	and	
finally	acting	on	platelets	to	impair	the	aggregatory	interactions,	by	
antagonising	GPVI	and	αIIbβ3	which	would	normally	protect	against	
bleeding.	MMP-	13	would	appear	therefore	to	modulate	the	architec-
ture	around	sites	of	infarction	to	increase	both	risk	of	stroke	and	its	
hemorrhagic	complications.	The	effect	of	MMP-	13	will	depend	upon	
its	local	level	and	the	exposure	of	MMP-	13-	binding	matrix	compo-
nents	and	warrants	further	investigation.
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